ON THE QUESTION OF INDICATIONS AND CHOICE OF THE METHOD OF PALLIATIVE SURGERY IN PATIENTS WITH STOMACH CANCER
##semicolon##
Key words: stage IV gastric cancer, palliative surgery, indications for hysterectomy, body weight, quality of life of patients##article.abstract##
Annotation: The article presents the results of palliative surgeries of varying scope
performed in 65 patients with stage IV gastric cancer. Indications for palliative surgery
were massive gastric bleeding or obstruction of various parts of the stomach. Life
expectancy of this category of patients is limited to several months in most cases, less
often - 1-2 years. Gastrostomy should be extremely limited and at the same time
indications for total gastrectomy should be expanded, which allows eliminating the
cause of obstruction and bleeding from the gastric tumor. During gastrectomy, the
formation of the esophageal-intestinal anastomosis can be performed using a suturing
device (SPTU, EEA). Patients who have undergone surgical interventions of varying
scope need to improve their quality of life, which is achieved by relieving the patient
of pain, creating the opportunity to eat, improving metabolic processes, preventing
rapid weight loss due to periodic intravenous infusions of colloidal and crystalloid
solutions (including fresh frozen plasma), maintaining mental status. Improving the
quality of life of a large contingent of doomed patients who have undergone various
levels of palliative surgical interventions should be considered the most important task
of practical health care.
##submission.citations##
1. LIST OF REFERENCES
2. Aggarwal C. et al. A phase 1, open-label, dose-escalation study of enoblituzumab
in combination with pembrolizumab in patients with select solid tumors // J.
Immunother. Cancer. - 2018. - Т. 6. - №. Suppl. 2. - С. 114.
3. Aleksander S. A. et al. The Gene Ontology knowledgebase in 2023 // Genetics. -
2023. - Т. 224. - №. 1. - С. iyad031.
4. Baj J. et al. Immunological aspects of the tumor microenvironment and epithelial-
mesenchymal transition in gastric carcinogenesis // International journal of
molecular sciences. - 2020. - Т. 21. - №. 7. - С. 2544.
5. Chen L. et al. Cancer associated fibroblasts promote renal cancer progression
through a TDO/Kyn/AhR dependent signaling pathway // Frontiers in Oncology. -
2021. - T. 11. - C. 628821.
6. Chen P., He Y., Zhou C. P47. 13 Galectin-9, A Novel Prognostic Factor in Small
Cell Lung Cancer // Journal of Thoracic Oncology. - 2021. - T. 16. - №. 3. - C.
S498.
7. Chocarro L. et al. Understanding LAG-3 signaling // International journal of
molecular sciences. - 2021. - T. 22. - №. 10. - C. 5282.
8. Compagno D. et al. Galectins as checkpoints of the immune system in cancers, their
clinical relevance, and implication in clinical trials // Biomolecules. - 2020. T. 10. -
№. 5. - C. 750.
9. Cui J. et al. Pancancer analysis of revealed TDO2 as a biomarker of prognosis and
immunotherapy //Disease Markers. - 2022. - T. 2022. - C. 1-18.
10. Doroshow D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint
inhibitors // Nature reviews Clinical oncology. - 2021. - T. 18. - №. 6. - C. 345362.
11. Edwards D. R., Handsley M. M., Pennington C. J. The ADAM metalloproteinases//
Molecular aspects of medicine. - 2008. - T. 29. - №. 5. - C. 258-289.
12. Elad-Sfadia G. et al. Galectin-3 augments K-Ras activation and triggers a Ras signal
that attenuates ERK but not phosphoinositide 3-kinase activity // Journal of
Biological Chemistry. - 2004. - T. 279. - №. 33. - C. 34922-34930.
13. Gooz M. ADAM-17: the enzyme that does it all // Critical reviews in biochemistry
and molecular biology. - 2010. - T. 45. - №. 2. - C. 146-169.
14. Gu L. et al. PD-L1 and gastric cancer prognosis: A systematic review and
metaanalysis // PloS one. - 2017. - T. 12. - №. 8. - C. e0182692.
15. He W. et al. CD155T/TIGIT signaling regulates CD8+ T-cell metabolism and
promotes tumor progression in human gastric cancer // Cancer research. - 2017. -T.
77. - №. 22. - C. 6375-6388.
16. Henson D. E. et al. Differential trends in the intestinal and diffuse types of gastric
carcinoma in the United States, 1973-2000: increase in the signet ring cell type //
Archives of pathology & laboratory medicine. - 2004. - T. 128. - №. 7. - C. 765770.
17. Heusschen R., Griffioen A. W., Thijssen V. L. Galectin-9 in tumor biology: a jack
of multiple trades // Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. -
2013. - T. 1836. - №. 1. - C. 177-185.
18. Huang D. W. et al. CD155 expression and its correlation with clinicopathologic
characteristics, angiogenesis, and prognosis in human cholangiocarcinoma //
OncoTargets and therapy. - 2017. - C. 3817-3825.
19. Iguchi-Manaka A. et al. Increased soluble CD155 in the serum of cancer patients //
PloS one. - 2016. - T. 11. - №. 4. - C. e0152982.
20. Joossens J. V. et al. Dietary salt, nitrate and stomach cancer mortality in 24
countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative
Research Group // International journal of epidemiology. - 1996. - T. 25. - №. 3. -
c. 494-504.
21. Keir M. E. et al. PD-1 and its ligands in tolerance and immunity // Annu. Rev.
Immunol. - 2008. - T. 26. - № 1. - C. 677-704.
22. Kim S. J. et al. Fascin expression is related to poor survival in gastric cancer //
Pathology international. - 2012. - T. 62. - №. 12. - C. 777-784.
23. Larsson S. C., Bergkvist L., Wolk A. Fruit and vegetable consumption and
incidence of gastric cancer: a prospective study // Cancer Epidemiology Biomarkers
& Prevention. - 2006. - T. 15. - №. 10. - C. 1998-2001.
24. Lee B. H. et al. Prognostic value of galectin-9 relates to programmed death-ligand
1 in patients with multiple myeloma // Frontiers in Oncology. - 2021. - T. 11. - C.
669817.
25. Li F. et al. CD4/CD8+ T cells, DC subsets, Foxp3, and IDO expression are
predictive indictors of gastric cancer prognosis // Cancer medicine. - 2019a. - T. 8.
- №. 17. - C. 7330-7344.
26. Li Y. C. et al. Overexpression of an immune checkpoint (CD155) in breast cancer
associated with prognostic significance and exhausted tumor-infiltrating
lymphocytes: a cohort study // Journal of immunology research. - 2020. - T. 2020.
- C. 1-9.
27. Li Y. et al. B7-H3 increases the radioresistance of gastric cancer cells through
regulating baseline levels of cell autophagy // American journal of translational
research. - 2019c. - Т. 11. - №. 7. - С. 4438-4449.
28. Linsley P. S. et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar
avidities but distinct kinetics to CD28 and CTLA-4 receptors // Immunity. - 1994.
Т. 1. - №. 9. - С. 793-801.
29. Liu H. et al. Increased expression of IDO associates with poor postoperative clinical
outcome of patients with gastric adenocarcinoma // Scientific Reports. -2016. - Т.
6. - №. 1. - С. 21319.
30. Lordick F. et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis,
treatment and follow-up^ // Annals of Oncology. - 2022. - Т. 33. - №. 10. - С. 1005-
1020.
31. Lu S. et al. Expression of indoleamine 2, 3-dioxygenase 1 (IDO1) and tryptophanyl-
tRNA synthetase (WARS) in gastric cancer molecular subtypes // Applied
immunohistochemistry & molecular morphology: AIMM. - 2020. - T. 28. - №. 5. -
C. 360-368.
32. Ma W. et al. Targeting immunotherapy for bladder cancer by using anti-CD3x
CD155 bispecific antibody //Journal of Cancer. - 2019. - T. 10. - №. 21. - C. 5153-
5161.
33. Mai P. L. et al. Risks of first and subsequent cancers among TP53 mutation carriers
in the National Cancer Institute Li-Fraumeni syndrome cohort // Cancer. - 2016. -
T. 122. - №. 23. - C. 3673-3681.
34. Masciari S. et al. Gastric cancer in individuals with Li-Fraumeni syndrome //
Genetics in Medicine. - 2011. - T. 13. - №. 7. - C. 651-657.
35. McDermott D. et al. Efficacy and safety of ipilimumab in metastatic melanoma
patients surviving more than 2 years following treatment in a phase III trial
(MDX010-20) // Annals of Oncology. - 2013. - T. 24. - №. 10. - C. 2694-2698.
36. Möller-Hackbarth K. et al. A disintegrin and metalloprotease (ADAM) 10 and
ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3
(Tim-3) // Journal of Biological Chemistry. - 2013. - T. 288. - №2. 48. - C.
3452934544.
37. Moss M. L. et al. Recent advances in ADAM17 research: a promising target for
cancer and inflammation // Mediators of inflammation. - 2017. - T. 2017. C. 121.
38. Nakahara S., Raz A. Regulation of cancer-related gene expression by galectin-3 and
the molecular mechanism of its nuclear import pathway // Cancer and Metastasis
Reviews. - 2007. - T. 26. - № 3-4. - C. 605-610.
39. Ochs K. et al. Tryptophan-2, 3-dioxygenase is regulated by prostaglandin E2 in
malignant glioma via a positive signaling loop involving prostaglandin E receptor-
4 // Journal of neurochemistry. - 2016. - T. 136. - №. 6. - C. 1142-1154.
40. Okada K. et al. Reduced galectin-3 expression is an indicator of unfavorable
prognosis in gastric cancer // Anticancer research. - 2006. - T. 26. - №. 2B. - C.
1369-1376.
41. Parsonnet J. et al. Helicobacter pylori infection in intestinal-and diffuse-type gastric
adenocarcinomas // JNCI: Journal of the National Cancer Institute. - 1991. T. 83. -
№. 9. - C. 640-643.
42. Patel S. P., Kurzrock R. PD-L1 expression as a predictive biomarker in cancer
immunotherapy // Molecular cancer therapeutics. - 2015. - T. 14. - №2. 4. - C.
847856.
43. Peyraud F. et al. Targeting tryptophan catabolism in cancer immunotherapy era:
challenges and perspectives // Frontiers in Immunology. - 2022. - T. 13. - C. 807271.
44. Kuliev A.A., Juraev M.D. и др. // Turkish Journal of Physiotherapy and
Rehabilitation; 32(3) 2021. C 7242-7245
45. Кулиев А.А., Джураев М.Д. и др. // Academic research in educational sciences
scientific journal 2021. №2. C 291-307
46. Кулиев А.А., Джураев М.Д. и др. // Журнал биомедицины и практики; №2
2021. C 132-138.
47. Kuliev A.A., Juraev M.D. и др. // The American Journal of Medical Sciences and
Pharmaceutical Research (ISSN – 2689-1026) 2023. C 70-77.
